Market Overview

UPDATE: Morgan Stanley Reiterates On Walgreen Company Ahead Of February Sales Report

Related WAG
Top 4 NYSE Stocks In The Drug Stores Industry With The Highest ROE
Walgreen Co. Or CVS Caremark: Which Would You Rather?
Cavuto: Call for Consistent Press Standards (Fox Business)

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Walgreen Company (NYSE: WAG), but removed the $68.00 price target.

In the report, Morgan Stanley noted, “WAG is scheduled to report February sales on Wednesday, March 5th before market open. February sales are the final month of WAG's 2QFY14 quarter. We expect a total sales comp of 4.8% y/y (vs. cons. of 4.6%), with no calendar day shift impact, up from an adj. comp of 3.2% in January. The February total sales comp reflects a pharmacy sales comp estimate of 6.3% vs. consensus of 6.1%, and a front-end comp estimate of 2.6% vs. consensus of 2.0%.”

Walgreen Company closed on Friday at $67.95.

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings


Most Popular

Related Articles (WAG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters